News

YEAR
ALL YEARS
  • 2024
  • 2023
  • 2022
  • All Years
April 9, 2024

Flare Therapeutics Presents Data at AACR 2024 Annual Meeting Characterizing PPARG-Derived Immune Cell Patterns in Urothelial Cancer Patients After Anti-PD1 Therapy

March 5, 2024

Flare Therapeutics to Present Immune Profiling Data from Urothelial Cancer Patients Treated with Anti-PD1 Therapy at AACR 2024 Annual Meeting

January 26, 2024

Flare Therapeutics Presents FX-909 Phase 1 Dose Escalation and Expansion Clinical Trial Design at the 2024 ASCO Genitourinary Cancers Symposium

--First-in-human trial evaluating safety, tolerability, and clinical activity of FX-909 in patients with advanced solid malignancies including advanced urothelial carcinoma--
November 3, 2023

Flare Therapeutics Presents New Translational Data in Support of Lead Asset FX-909 for the Treatment of Muscle-Invasive Urothelial Cancer at SITC 2023 Annual Meeting

--Poster presentation proposes targeting PPARG for the treatment of muscle-invasive urothelial cancer (MIUC) may help overcome resistance to immunotherapy--
October 31, 2023

Flare Therapeutics to Present New Translational Data in Support of Clinical Candidate FX-909’s Phase 1 Development at SITC 2023 Annual Meeting

October 19, 2023

Flare Therapeutics Announces First Patients Dosed in First-in-Human Phase 1 Clinical Study of FX-909 in Advanced Solid Malignancies, Including Urothelial Cancer

FX-909 is a first-in-class small molecule inhibitor of the PPARG transcription factor for the potential treatment of advanced urothelial carcinoma
October 13, 2023

Flare Therapeutics Presents Novel, AI-Based Method Identifying Luminal Subtype of Urothelial Cancer Supporting Lead Asset FX-909 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 4, 2023

Flare Therapeutics to Present Biomarker Data for Clinical Candidate FX-909 at 2023 AACR-NCI-EORTC International Conference

May 9, 2023

Flare Therapeutics Named to Inc. Magazine’s Annual List of Best Workplaces for 2023

April 17, 2023

Flare Therapeutics Presents First Preclinical Data on Lead Asset FX-909, a Novel Small Molecule PPARG Inhibitor to Potentially Treat Urothelial Cancer, at the 2023 AACR Annual Meeting

April 13, 2023

Caris Life Sciences and Flare Therapeutics Announce Strategic Preferred Portfolio Partnership to Advance Flare’s Precision Oncology Pipeline

March 30, 2023

Flare Therapeutics Further Strengthens Leadership Team with Key Executive Appointments and Promotions

Michael L. Meyers, M.D., Ph.D. to join as Chief Medical Officer; Daphne Karydas promoted to President and Chief Financial Officer; Michaela Bowden, Ph.D., promoted to Chief Development Officer; and Jigar Raythatha joins the Board of Directors
March 22, 2023

Flare Therapeutics Announces Oversubscribed $123 Million Series B Financing

Led by GordonMD® Global Investments LP and Pfizer Ventures, financing to support advancement of FX-909, a first-in-class PPARG inhibitor, into the clinic in 2023, along with continued development of Flare’s platform and pipeline of novel transcription factor targets in oncology
March 14, 2023

Flare Therapeutics to Present Overview of Clinical Candidate FX-909 at AACR Annual Meeting

Robert Sims, Ph.D., Chief Scientific Officer and co-founder of Flare Therapeutics, will present the discovery of its clinical candidate, FX-909, at the AACR Annual Meeting in Orlando, FL
February 2, 2023

Flare Therapeutics to Present at Guggenheim Healthcare Talks Oncology Day

Robert Sims, Ph.D., Chief Scientific Officer and co-founder at Flare Therapeutics, will present a company overview at the upcoming Guggenheim Healthcare Talks Oncology Day in New York, NY
November 22, 2022

Flare Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference

Daphne Karydas, Chief Operating Officer and Chief Financial Officer of Flare Therapeutics, will present a company overview at the Piper Sandler 34th Annual Healthcare Conference being held in New York, NY
October 28, 2022

Flare Therapeutics Presents Comprehensive Real-World Data in Advanced and Metastatic Urothelial Cancer in Support of Therapeutic Targeting of PPARG at 2022 EORTC-NCI-AACR Symposium

Molecular Real-World Data (RWD) from 3,000+ individuals with advanced and metastatic urothelial cancer highlight Peroxisome Proliferator-Activated Receptor Gamma (PPARG) as a lineage defining transcription factor is foundational to Flare’s precision oncology approach
October 26, 2022

Flare Therapeutics Presents Preclinical Data that Show Potential of Novel PPARG Inhibitors to Treat Urothelial Cancer at 2022 EORTC-NCI-AACR Symposium

Data highlight the potential for novel small molecule inhibitors of key transcription factors to target and effectively treat advanced UC
July 25, 2022

Flare Therapeutics Appoints Amit Rakhit, M.D. as President and Chief Executive Officer

Biopharma industry veteran to lead advancement of company’s transcription factor-focused pipeline into clinical stage and expand discovery efforts
April 26, 2022

Flare Therapeutics Appoints Adrian Jubb as Chief Medical Officer

Dr. Jubb’s research and clinical development experience strongly positions company for clinical excellence in advancing precision oncology pipeline
October 25, 2021

Flare Therapeutics Appoints Daphne Karydas as COO and CFO, and Michaela Bowden, PhD, as SVP of Biology and Translation

Company expands leadership team across business and science as it advances precision oncology pipeline
May 13, 2021

Flare Therapeutics Launches with $82 Million Series A Financing to Advance Precision Oncology Pipeline based on Novel Drug Discovery Approach for Transcription Factors

Company has pioneered ‘switch site’ approach to uncover druggable regions within well validated, but elusive, transcription factors that are master regulators of gene expression

SHINING LIGHT ON PROGRESS

  PRESENTATIONS & PUBLICATIONS

 

This links to an external website.

Continue